|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Taltz
|
|
gptkbp:chemical_formula
|
C6420 H9920 N1716 O1984 S44
|
|
gptkbp:clinical_trial
|
gptkb:AXIS-1
gptkb:AXIS-2
gptkb:AXIS-3
gptkb:SPIRIT-1
gptkb:SPIRIT-2
gptkb:SPIRIT-3
gptkb:UNCOVER-1
gptkb:UNCOVER-2
gptkb:UNCOVER-3
Phase 3
|
|
gptkbp:clinical_use
|
treatment of autoimmune diseases
|
|
gptkbp:contraindication
|
active infections
hypersensitivity reactions
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:effective_date
|
gptkb:2016
|
|
gptkbp:frequency
|
once every 4 weeks after initial doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ixekizumab
|
|
gptkbp:indication
|
active ankylosing spondylitis
active psoriatic arthritis
moderate to severe plaque psoriasis
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_vulnerable_to
|
may induce anti-drug antibodies
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits IL-17 A
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 13 days
|
|
gptkbp:research_areas
|
rheumatology
dermatology
biologics
immunology
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:side_effect
|
headache
nausea
injection site reactions
thrombocytopenia
upper respiratory infections
neutropenia
serious infections
malignancies
liver enzyme elevations
|
|
gptkbp:storage
|
refrigerated at 2-8° C
|
|
gptkbp:targets
|
gptkb:IL-17_A
|
|
gptkbp:used_for
|
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
psoriasis
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:Taltz
|
|
gptkbp:bfsLayer
|
5
|